Insider Selling: Billiontoone (NASDAQ:BLLN) Insider Sells $880,000.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $110.00, for a total transaction of $880,000.00. Following the completion of the transaction, the insider directly owned 208,000 shares in the company, valued at approximately $22,880,000. The trade was a 3.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shan Riku Sakakibara also recently made the following trade(s):

• On Monday, June 8th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $98.22, for a total transaction of $785,760.00.

Billiontoone Price Performance

BLLN opened at $118.17 on Monday. The firm’s 50 day simple moving average is $92.57 and its two-hundred day simple moving average is $87.20. The company has a market capitalization of $5.44 billion and a PE ratio of 214.85. Billiontoone, Inc. has a 1-year low of $61.96 and a 1-year high of $138.70. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18.

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The business had revenue of $108.39 million for the quarter, compared to the consensus estimate of $95.81 million. The company’s revenue was up 83.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.39) EPS. As a group, equities analysts forecast that Billiontoone, Inc. will post 0.93 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on BLLN. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Wells Fargo & Company lowered their price objective on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 5th. Wall Street Zen upgraded Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Guggenheim increased their target price on shares of Billiontoone from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Finally, JPMorgan Chase & Co. raised their target price on shares of Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Billiontoone has a consensus rating of “Moderate Buy” and a consensus price target of $125.29.

Hedge Funds Weigh In On Billiontoone

Several large investors have recently made changes to their positions in the business. Rossby Financial LCC purchased a new stake in shares of Billiontoone during the fourth quarter worth about $25,000. Wells Fargo & Company MN purchased a new position in Billiontoone in the 4th quarter worth approximately $76,000. Smartleaf Asset Management LLC bought a new position in Billiontoone in the 4th quarter worth approximately $80,000. Nano Cap New Millennium Growth Fund L P bought a new position in Billiontoone in the 4th quarter worth approximately $82,000. Finally, Renaissance Capital LLC purchased a new stake in Billiontoone during the 4th quarter valued at approximately $201,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.